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INTRODUCTION
Patients undergoing autologous marrow or peripheral
blood stem cell rescue after myeloablative conditioning
regimens require prophylaxis for herpes simplex virus
(HSV) reactivation if they are seropositive for HSV prior to
stem cell transplantation [1-3]. Various schedules of pro-
phylaxis have been published, and most of these have used
intravenous (IV) acyclovir (ACY) at a dosage of 250 mg/m2
every 8 or 12 hours [4,5]. Some regimens begin in parallel
with the conditioning regimen, and others begin at the time
of stem cell reinfusion. Some regimens end with engraft-
ment of neutrophils, but others extend until day +30 or day
+100 posttransplantation. The use of IV ACY contributes
substantially to the cost of the autologous transplantation
procedure [6].
Valacyclovir (VAL) (Valtrex) is the L-valyl ester of ACY.
Because of its superior oral bioavailability (50% versus
approximately 12% for oral ACY) [7], use of oral VAL can
result in plasma concentrations equivalent to levels achieved
with IV ACY. Use of oral VAL instead of IV ACY could
potentially result in cost savings without an expected sacriﬁce
of efﬁcacy in HSV prophylaxis [8]. The only disadvantage to
use of oral VAL would be intolerance for oral medications
during periods of neutropenia and mucositis during the nadir
period of the transplantation. The ready water-solubility of
the VAL caplet may allow for use of liquid suspension prepa-
rations on those days when the caplets cannot be swallowed.
We therefore undertook a randomized study to compare IV
ACY versus VAL for HSV prophylaxis in the autologous
stem cell transplantation setting. The primary objectives of
the study were to compare cost of HSV prophylaxis between
study groups in the autologous transplantation setting and to
document the number of days patients were unable to take
either the VAL caplets or the liquid suspension. Incidence of
HSV infections in patients receiving oral VAL versus IV
ACY prophylaxis was also documented.
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ABSTRACT
Patients who are seropositive for herpes simplex virus (HSV) and are undergoing autologous marrow or peripheral
blood stem cell transplantation require prophylaxis for HSV infection. Most prophylaxis regimens have used intra-
venous acyclovir (ACY). Oral valacyclovir (VAL), the L-valyl ester of ACY, can be used to achieve plasma concentra-
tions equivalent to levels achieved with intravenous ACY. In this study, adults undergoing autologous stem cell
transplantation were randomized to receive ACY, 250 mg/m2 intravenously (IV) every 12 hours from day 0 to
engraftment, or VAL, 1 g orally every 12 hours from day 0 to engraftment. The primary study objective was to com-
pare cost of HSV prophylaxis between study groups. Thirty patients were randomized to receive either oral VAL
(n = 14) or IV ACY (n = 16) prophylaxis. Mean pharmacy cost of HSV prophylaxis in the patient group randomized
to IV ACY was $l080 versus $320 for the group randomized initially to VAL. This study demonstrates the feasibility
and significant cost savings of using oral VAL for HSV prophylaxis.
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PATIENTS AND METHODS
Study Design 
All HSV seropositive adult patients who were undergo-
ing autologous stem cell transplantation during the time-
frame of the study were offered study participation. Those
who gave informed consent in accordance with policies of
the Research Subjects Review Board of the University of
Rochester were randomized to 1 of 2 prophylaxis regimens
in a nonblinded fashion using a computer program main-
tained by the Department of Biostatistics. The 2 regimens
examined were: (1) ACY 250 mg/m2 IV twice per day (BID)
from day 0 (day of stem cell infusion) until the day of
engraftment (absolute neutrophil count [ANC] >500/mm3
for 3 consecutive days) or discharge, whichever occurred
ﬁrst and (2) VAL, 1 g BID from day 0 (day of stem cell infu-
sion) until the day of engraftment (ANC >500/mm3 for
3 consecutive days) or discharge. VAL could be taken either
as caplets or as an oral suspension. On days when patients
had mucositis or gastrointestinal status that precluded swal-
lowing the VAL caplets, nursing staff dissolved the caplets in
≥30 mL liquid of the patient’s choice. If patients were
unable to ingest either preparation, IV ACY was substituted
at a dosage of 250 mg/m2 every 12 hours on those days only.
Seropositive patients were excluded only if (1) measured or
calculated creatinine clearance was <50 mL/min or serum
creatinine was >2.0 mg/dL prior to beginning the condi-
tioning regimen, (2) known allergic reactions to either ACY
or VAL had occurred in the past, or (3) known active HSV
infection was present at time of prophylaxis initiation.
Variables Monitored during the Study 
Doses of both ACY and VAL for patients with renal
impairment were adjusted based on published recommenda-
tions. Patients were monitored daily with complete blood
counts and chemical proﬁles. Hepatic enzymes were checked
3 times per week. Patient mucositis was graded daily accord-
ing to the Nebraska scale [9] by staff nurses assigned to the
patient. A pharyngeal viral culture for HSV was performed
on day 0, day +10, and day +30 or ﬁrst visit after discharge.
Data Analysis
Pharmacy costs were compared for those patients ran-
domized to the VAL versus the ACY treatment arm, and the
extent to which patients were unable to ingest VAL in either
caplet or liquid form was documented. It was determined
that with 15 patients per treatment arm, the study would
have 90% power to detect a dollar cost ratio of 2.0 between
the VAL and ACY groups. Means and standard deviations
were calculated, and differences between subject groups
were analyzed using the Student t test.
RESULTS
Thirty patients were randomized to receive either VAL
(n = 14) or ACY (n = 16). During the time frame of the study,
125 patients underwent autologous stem cell transplantation
at the University of Rochester and were screened for this
study. The opportunity to participate in the study was pre-
sented to 45 eligible patients, 15 of whom refused participa-
tion. The most common reason for patient exclusion during
screening was HSV seronegativity. One patient had an unex-
pected positive result for an HSV culture obtained at day 0.
This patient had been asymptomatic without oral lesions and
was randomized to the VAL treatment arm. Results of HSV
cultures at day +10 and day +30 were subsequently negative.
No other patients developed documented HSV infection
during treatment or follow-up to 30 days. Patient demograph-
ics are shown in Table 1. The mean age was the same for the
patients in the ACY and VAL treatment groups. The majority
of patients enrolled had lymphoma or myeloma, and all
patients received myeloablative conditioning in the form of (1)
BEAC (300 mg/m2 1,3-bis(2-chloroethyl)-1-nitrosourea
[BCNU], 800 mg/m2 cytarabine [Ara-C], 800 mg/m2 etopo-
side [VP-16], and 140 mg/kg cyclophosphamide total), (2)
BEAM (140 mg/m2 melphalan replacing the cyclophos-
phamide of the BEAC regimen, (3) BU/CY (16 mg/kg
busulfan and 200 mg/kg cyclophosphamide), (4) melphalan
(200 mg/m2), or, for the 2 breast cancer patients, (5) MEC
Table 1. Patient Demographics
Overall VAL Arm ACY Arm
Total 30 14 16
Sex
Male 14 4 10
Female 16 10 6
Age, median (range), y 50.0 48.5 50.0
(26-69) (27-69) (26-65)
Diagnosis
Lymphoma 13 7 6
Breast cancer 3 2 1
Acute myelogenous leukemia 4 1 3
Multiple myeloma 10 4 6
Conditioning regimen
BCNU/VP-16/Ara-C/CY 11 4 7
BCNU/VP-16/Ara-C/melphalan 2 2 0
Busulfan/cytoxan 4 3 1
Melphalan/VP-16/carboplatin 2 1 1
Melphalan 10 4 6





Overall Oral Only Oral/IV ACY Arm
Maximum mucositis grade, mean (range) 14.5 (11-20) 13.2 (11-15) 15.5 (14-17) 14.5 (12-20)
Days at maximum grade, mean (range) 2 (1-6) 1.7 (1-4) 2.5 (1-6) 2 (1-5)
No. of patients requiring hyperalimentation 3 0 1 2
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(800 mg/m2 carboplatin, 800 mg/m2 VP-16, and 100 mg/m2
melphalan total). One patient with breast carcinoma received
the STAMP-I regimen (high-dose cyclophosphamide, cis-
platin, and BCNU). All patients received a peripheral blood
stem cell (PBSC) graft.
The mean of the maximum mucositis grade recorded
for the VAL versus ACY groups did not differ, nor did the
number of days for which the maximum mucositis grade was
recorded (Table 2). Mucositis was scored according to the
Nebraska scoring system, which has a range from 8 to 24.
Those patients who were able to complete prophylaxis with
oral VAL had a mean maximum mucositis grade of 13 ± 1.7,
whereas those who required some doses of IV ACY in addi-
tion to oral VAL had a mean maximum score of 15.6 ± 0.98
(P < .01 by 2-sided t test). Only 3 patients received hyperali-
mentation during any portion of their transplantation. Time
to either neutrophil or platelet engraftment was not signiﬁ-
cantly different between the 2 treatment arms (Table 3).
Only 6/14 (43%) of patients randomized initially to
receive VAL required no ACY doses, whereas the other 8
required from 2 to 21 doses of IV ACY to complete HSV pro-
phylaxis because of mucositis, nausea, or both (Table 4). Those
patients who were able to complete prophylaxis with VAL
alone received a mean of 24 doses. Patients randomized ini-
tially to ACY received a mean of 27 doses. Those initially ran-
domized to VAL but switched to ACY because of intolerance
received on average 15 doses of VAL and 12 doses of ACY
(Table 4). Pharmacy costs during the study period were $2.50
per VAL dose and $40.00 per IV ACY dose. The mean cost of
HSV prophylaxis for the group randomized initially to VAL
was $320. Mean cost per patient was $59 ± $13.54 for patients
able to complete prophylaxis with VAL alone versus $517 ±
$318 for those needing to switch to ACY versus $1083 ± $198
for those randomized to ACY initially (P < .001 for mean VAL
group costs versus mean ACY group costs) (Figure).
DISCUSSION
Mucosal HSV reactivation may occur in immunosup-
pressed subjects, and in some cases visceral dissemination or
organ involvement can occur [10]. IV administration of ACY
has been used for prophylaxis because of the low oral bioavail-
ability of ACY (20%) and unpredictable absorption in stem
cell transplantation patients with mucositis [11,12]. Both VAL
and famciclovir have greater oral bioavailability than does oral
ACY [13]. VAL is the L-valyl ester of ACY, and after conver-
sion to ACY by hepatic and intestinal pathways, bioavailability
of oral VAL is 3 to 5 times higher than that of oral ACY [7].
Previously, prospective, double-blinded, placebo-controlled
studies have shown that ACY versus placebo was effective in
preventing HSV reactivation when begun 3 days prior to
bone marrow transplantation (BMT) and continued for
18 days [12]. Subsequent studies also conﬁrmed the value of
HSV prophylaxis in BMT patients [11], and resistance was
found to develop only rarely during HSV prophylaxis [14].
This study demonstrates that the use of oral VAL as
prophylaxis for HSV infections in the autologous stem cell
transplantation setting results in significant cost-saving
potential compared with the use of IV ACY. The cost sav-
ings calculated here involved pharmacy costs, but costs of
preparation and administration of an IV drug are also con-
siderations. Because the incidence of HSV reactivation dur-
ing prophylaxis is low [12], this study was not powered to
detect efficacy differences between the 2 prophylaxis regi-
mens. No documented infections occurred during the
period of screening, except for the patient who had an unex-
pectedly positive baseline culture.
No side effects attributable to oral VAL affected trans-
plantation course or engraftment, and at the 1-g BID dosage
used here, no instances of thrombotic microangiopathy,
which has been seen with higher doses of VAL (8 g/day),
were noted [15]. A 500-mg BID dosage may be an effective
prophylaxis dosage as well but would need to be examined
in a randomized fashion. One previous study has retrospec-
tively examined a 500-mg BID VAL dosage for HSV pro-
phylaxis in autologous stem cell transplantation patients
[16]. We chose 1 g BID as the dosage most equivalent to the
250 mg/m2 dosage of IV ACY usually recommended for
HSV prophylaxis in the stem cell transplantation setting [8].
This study also demonstrates that although the use of
VAL was feasible in a population of patients undergoing
myeloablative conditioning followed by autologous blood pro-
genitor cell infusions, a significant proportion of patients
receiving VAL required some doses of IV ACY to complete
HSV prophylaxis because of mucositis and other gastrointesti-
nal side effects. Nevertheless, the use of VAL, when tolerated
from a gastrointestinal standpoint, resulted in significant
Table 3. Engraftment
VAL Arm
Overall Oral Only Oral/IV ACY Arm
Days to ANC ≥500, mean (range) 11.6 (9-18) 10.8 (10-12) 11 (9-13) 12.3 (10-18)
Days to platelet count ≥20,000, mean (range) 13.9 (9-41) 12.3 (9-15) 15.9 (10-41) 13.4 (9-19)
Table 4. Total Cost of HSV Prophylaxis
Valacyclovir
No IV
Required IV Required Acyclovir
(n = 6) (n = 8) (n = 15)*
Valacyclovir, no. of doses
Total 141 119 0
Mean 24 15 0
Acyclovir, no. of doses
Total 0 93 406
Mean 0 12 27
Range (2-21) (22-36)
Mean cost/patient $59 $518 $1083
*Data missing on 1 patient.
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cost savings, and no patients developed documented HSV
infections during the monitoring period of this study (up to
day +30 posttransplantation), although this study was not
powered to demonstrate equivalent efficacy. Further
prospective studies of VAL use for HSV prophylaxis in both
allogeneic and autologous stem cell transplantation patients
would appear to be warranted.
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